Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best Cell phone Brands for Tech Aficionados - 2Meet the Stars of the Feline World: Well known Pet Feline Varieties
- 3An Extended time of Self-Reflection: Self-awareness through Journaling
- 4Flu season is ramping up, and some experts are "pretty worried"
- 5Step by step instructions to Pick the Right Web-based Degree Program
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
- Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- The Most Compelling Books of the 10 years
- Drenched in Pixels: A Survey of \Vivid Interactivity Experience\ Game
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Vote In favor of Your Number one Game Control center
- Pick Your Favored kind of soup
